Apixaban, an oral, direct inhibitor of activated Factor Xa
Shantsila, E.; Lip, G.Y.H.
Current Opinion in Investigational Drugs 9(9): 1020-1033
2008
ISSN/ISBN: 1472-4472 PMID: 18729009 Document Number: 628008
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.
Document emailed within 1 workday
Related Documents
He, W.J.; Hu, Y.; Zhang, X.P.; Hong, M.; Guo, T.; Wei, W.N.; Song, S.J. 2008: Activated protein C ratio, plasma tissue factor activity and activated factor VIi in Chinese patients with coronary heart disease European Journal of Medical Research 13(2): 47-51Yi, W.-Q.; Gan, H.-T.; Huang, X.-L.; Zhang, M.; Ouyang, Q. 2007: The effects of p38 mitogen activated protein kinase inhibitor SB203580 on colonic mucosa tumor necrosis factor alpha expression in ulcerative colitis Zhonghua Nei Ke Za Zhi 46(9): 747-750
Chen, S.; Li, G.; Xu, L.; He, Z. 1999: Affection of aprotinin on tissue factor pathway inhibitor in peri-operation of cardiac direct vision operation Hunan Yi Ke da Xue Xue Bao 24(1): 26-28
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Kjalke, M.; Monroe, D.M.; Hoffman, M.; Oliver, J.A.; Ezban, M.; Hedner, U.; Roberts, H.R. 1998: The effects of activated factor VIi in a cell-based model for tissue factor-initiated coagulation Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S21-S25
Monroe, D.M.; Hoffman, M.; Oliver, J.A.; Roberts, H.R. 1998: A possible mechanism of action of activated factor VIi independent of tissue factor Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S15-S20
Pfyffer, M.; Kistler, H.J.; von Felten, A. 1983: Acquired hemophilia a due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR Schweizerische Medizinische Wochenschrift 113(40): 1456-1459
Wang, H-ping.; Chen, X-ping.; Ding, L.; He, S-qing.; Ali, M.; Li, D-hua.; Zhang, W-guang. 2003: Hepatitis B x protein activated vascular endothelial growth factor expression through hypoxia inducible factor-1 pathway Zhonghua Zhong Liu Za Zhi 25(5): 433-436
Dahlbäck, B. 1997: Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis Thrombosis and Haemostasis 78(1): 483-488
Hofmann, V.; Ermanni, M.; Straub, P.W. 1978: Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings) Schweizerische Medizinische Wochenschrift 108(41): 1600
Baishev, I.M.; Zubairov, D.M. 1986: Effect of a factor XIi inhibitor isolated from kernels of corn on the cold activation of factor VIi in blood plasma Gematologiia i Transfuziologiia 31(4): 32-35
Richard, C.; Sedano, C.; Cuadrado, M.A.; Iriondo, A.; Bello, C.; Gandarillas, M.A.; Zubizarreta, A. 1986: Effect of a thymic factor on the concentration of a factor VIIi inhibitor in a patient with treated Hodgkin's disease Thrombosis and Haemostasis 55(2): 299-300
Van der Meer, F.J.; van Tilburg, N.H.; van Wijngaarden, A.; van der Linden, I.K.; Briët, E.; Bertina, R.M. 1989: A second plasma inhibitor of activated protein C: alpha 1-antitrypsin Thrombosis and Haemostasis 62(2): 756-762
Lindhout, T.; Franssen, J.; Willems, G. 1995: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor Thrombosis and Haemostasis 74(3): 910-915
Karahan-Gül, O.; van Loosdrecht, M.C.M.; Orhon, D. 2003: Modification of Activated Sludge Model no. 3 considering direct growth on primary substrate Water Science and Technology: a Journal of the International Association on Water Pollution Research 47(11): 219-225
Otsubo, O.; Kuzuhara, K.; Simada, Y.; Yamauchi, Y.; Takahashi, I.; Yamada, Y.; Otsubo, K.; Inou, T. 1979: Treatment of uraemic peripheral neuritis by direct haemoperfusion with activated charcoal Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 16: 731-732
Hule, V. 1975: Factor IX inhibitor (antihemophilic factor B, PTC) in a woman Vnitrni Lekarstvi 21(3): 274-277
Jones, T.R.; Charette, L.; Garcia, M.L.; Kaczorowski, G.J. 1990: Selective inhibition of relaxation of guinea-pig trachea by charybdotoxin, a potent Ca(++)-activated K+ channel inhibitor Journal of Pharmacology and Experimental Therapeutics 255(2): 697-706